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Abstract Using the trans-methoxyvinylpyrene analogues of
benzo[a]pyrene-7,8-dihydrodiol (MVP) as a singlet oxygen
(1O2) chemiluminescence probe, we have demonstrated that
guinea pig eosinophils release 1O2 when activated with the
physiological agonists C5a and leukotriene B4. This release,
which occurs at agonist concentrations as low as 1037 M, occurs
more rapidly than activation with phorbol ester (1036 M), is
similar in level, but is more transitory. In addition, the release of
1O2 occurs in the absence of added bromide ions and represents,
we propose, an important feature of eosinophil-mediated
inflammatory damage.
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1. Introduction
There is considerable evidence to suggest the importance of
eosinophils in the pathogenesis of allergic diseases, such as
asthma, and in the defence against invading parasitic larvae
of helminths [1^3]. Eosinophils are characteristically tissue-
associated cells and it is at these sites that they release several
mediators, which are though to mediate damage to host cells
or cytotoxic e¡ects on parasites. These mediators include lipid
substances, such as platelet-activating factor and thrombox-
anes, and basic proteins, such as major basic protein (MBP)
[4^6]. In addition, there is evidence demonstrating that acti-
vated eosinophils release reactive oxygen species (ROI) such
as hydrogen peroxide and superoxide anion, as well as nitric
oxide [7^9]. Together these reactive intermediates can cause
injury to host tissues and parasitic larvae. In addition, phor-
bol myristate acetate (PMA)-activated human eosinophils
have been shown to release singlet oxygen (1O2), however
this was only in the presence of bromide ion [10] and its
physiological relevance has not been investigated. Eosinophils
produce 1O2 via the Mallet reaction (Eq. 2) between H2O2
and hypobromous acid (HOBr), formed Eq. 1).
H2O2  Br3 ÿ!peroxidaseHOBrH2O 1
HOBrH2O2 ! 1O2 HBrH2O 2
1O2 arises because, unlike hypochlorous acid (HOCl), HOBr
is not as rapidly quenched by reactions with endogenous
amines (Eq. 3) and is therefore free to react with H2O2 [11].
H H
HOCl  COOHÿCÿNH2 ! COOHÿCÿNHCL
R R
3
The ability of mediators which induce eosinophil recruitment
in vivo and activation in vitro to elicit 1O2 production in
eosinophils has not yet been investigated. We have therefore
used puri¢ed guinea pig eosinophils, to investigated whether
the chemoattractant molecules C5a and leukotriene B4
(LTB4), which we have previously shown to activate eosino-
phils in vitro leading to their homotypic aggregation and re-
lease of superoxide anion [12], are also able to stimulate 1O2
production. A comparison with optimal activation induced by
PMA, an activator of protein kinase C, was also made. We
have employed the trans-methoxyvinylpyrene analogue of
benzo[a]pyrene-7,8-dihydrodiol (MVP) as a 1O2 chemilumi-
nescence probe [13].
2. Materials and methods
2.1. Reagents
Hanks’ solutions, HEPES and horse serum were purchased from
Life Technologies Limited (Paisley, UK) and Percoll was from Phar-
macia (Milton Keynes, UK). Superoxide dismutase, glucose oxidase,
xanthine oxidase, lucigenin, xanthine phorbol myristate acetate, were
purchased from Sigma Chemical Co., Poole, UK. C5a and LTB4 were
purchased from Bachem, UK. Myeloperoxidase was a gift from Dr Jo
Cambridge (Department of Rheumatology, University College Lon-
don), the 5-methoxyvinylpyrene analogue of 7,8-diol was a gift from
Dr Harold Hodson (Wellcome Research Laboratories, Beckenham,
UK) and L-N-(1-iminoethyl)-ornithine (L-NIO) was a gift from Pro-
fessor Salvador Moncada (The Wolfson Institute, University College
London).
2.2. Isolation and puri¢cation of guinea pig eosinophils
Eosinophils were prepared by the method of Teixeira et al., [14].
Brie£y, ex-breeder female guinea pigs (Harlan Porcellus; 700^800 g)
were treated with horse serum (1 ml i.p.) every other day for 2^3
weeks and cells collected by peritoneal lavage with heparinised saline
(10 IU/ml) 2 days after the last injection. The cells obtained were
layered onto a discontinuous Percoll-HBSS (calcium- and magnesi-
um-free) gradient and centrifuged (1500Ug, 25 min at 20‡C). Eosino-
phils (s 95% pure as evaluated by stained smears prepared by cyto-
centrifuge and s 98% viable as evaluated by trypan blue exclusion)
were collected from the 1.090/1.095 and 1.095/1.100 g/ml density in-
terfaces. The puri¢ed eosinophils were then washed twice in HBSS
containing 0.25% BSA and resuspended prior to analysis in HBSS
with BSA at a ¢nal concentration of 107 cells/ml.
2.3. Chemiluminescent measurement of singlet oxygen and superoxide
The methoxyvinylpyrene analogue of benzo[a]pyrene-7,8-dihydro-
diol (MVP) was synthesised by the method of Posner et al. [13].
Samples (2 ml in 35-mm sealed culture grade dishes) were kept in a
light-tight chamber at 37‡C. Chemiluminescence was measured using
a luminometer incorporating a gallium arsenide photomultiplier tube
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(Hamamatsu), cooled to 320‡C, with a response above 10% of quan-
tum e⁄ciency in the wavelength range 200^900 nm. Light emission
was characterised using speci¢c enhancers of chemiluminescence: 10
WM lucigenin for superoxide, and 10 WM MVP for singlet oxygen.
Chemiluminescence was measured from the time of addition of ago-
nist every 5 min for a total time of 20 min. Counts for each time point
were collected over 100 s with a 1-s gate time.
2.4. Generation of superoxide, free hydroxyl, nitric oxide, peroxynitrite
and singlet oxygen
Superoxide was generated enzymatically from 0.33 U of xanthine
oxidase, and acetaldehyde (10 WM) in PBS. Hydroxyl radicals were
generated in a system containing 200 WM hydrogen peroxide with 10
WM Fe3/EDTA, nitric oxide from homolytic breakdown of S-nitro-
socysteine at 37‡C and pH 7.4. Peroxynitrite, prepared free of hydro-
gen peroxide by ozone and azide [15], and was added as a bolus.
Singlet oxygen was generated from hypobromous acid and hydrogen
peroxide produced using a myeloperoxidase, sodium bromide, and
glucose oxidase-glucose cell-free system. Kodak Wratten ¢lters, cut-
o¡ 703 nm (680^720) and 470 nm (460^500), were used to demon-
strate 1O2-mediated non- and MVP-enhanced chemiluminescence re-
spectively [16].
3. Results
3.1. Lucigenin and MVP chemiluminescence in the presence of
superoxide, singlet oxygen, nitric oxide, peroxynitrite and
hydroxyl
Superoxide produced from xanthine oxidase and acetalde-
hyde caused a SOD-inhibitable lucigenin chemiluminescence
(Fig. 1A). The addition of MVP to xanthine oxidase and
acetaldehyde induced no chemiluminescent signal above back-
ground (Fig. 1). In a system producing hydrogen peroxide
from glucose and glucose oxidase, neither background,
MVP nor lucigenin chemiluminescence was observed (data
not shown), however when myeloperoxidase was added, back-
ground (non-enhanced) chemiluminescence and MVP chemi-
luminescence was produced (Fig. 1b). Chemiluminescence
was immediate, reached a peak after 30 s, and was enhanced
5-fold with MVP. Non- and MVP-enhanced chemilumines-
cence was blocked by the respective ¢lters (data not shown).
Addition of S-nitrosocysteine, which rapidly releases NO, or a
hydroxyl radical-generating system of Fe3/EDTA did not
result in chemiluminescence with MVP. Peroxide-free per-
oxynitrite (10 WM) caused an immediate chemiluminescence
of 2500 cps which decayed to basal levels in 20 s.
3.2. E¡ect of PMA on eosinophil MVP chemiluminescence
Addition of PMA to eosinophils caused a time- and dose-
dependent increase in MVP chemiluminescence (Fig. 2a). The
chemiluminescence increased linearly, reaching a peak (200
cps) after 10 min, which was sustained to the end of monitor-
ing (20 min). This PMA-induced increase in chemilumines-
cence was blocked using a 460^500-nm ¢lter but was unaf-
fected by SOD (Fig. 2b). In contrast, the e¡ects of PMA on
lucigenin chemiluminescence were markedly reduced in the
presence of SOD (Fig. 2b).
3.3. Identi¢cation of singlet oxygen as the source of MVP
chemiluminescence from PMA-activated eosinophils
To exclude peroxynitrite as a source of MVP chemilumi-
nescence during eosinophil activation cells were pre-treated
for 10 min with the nitric oxide synthase inhibitor L-NIO
(100 WM). This had no e¡ect on chemiluminescence (Fig. 3)
and by inhibiting NO formation precludes peroxynitrite for-
mation as a source of emission. The singlet oxygen quencher
histidine (2 mM), but not the hydroxyl radical quencher man-
nitol (2 mM), decreased MVP chemiluminescence by 80%.
3.4. Stimulation of eosinophil singlet oxygen release by
physiological agonists
The physiological chemoattractants C5a and LTB4, used at
a concentration of 1037 M, induced a transient rise in MVP
chemiluminescence which was faster than that observed with
PMA, reaching a peak 5 min following agonist addition (Fig.
4), after which there was a fall in chemiluminescence to levels
which were still higher than the background. Thus, the level of
chemiluminescence detected was similar to that detected in
response to activation with 1036 M PMA, but it was not
sustained.
4. Discussion
Eosinophils play an important role in defence against in-
vading parasites and in the pathophysiology of allergic dis-
Fig. 1. a: Non-, lucigenin (LUC)- and MVP-enhanced chemiluminescence in a xanthine oxidase plus acetaldehyde superoxide-generating system.
b: Non- and MVP-enhanced chemiluminescence with singlet oxygen (glucose oxidase-myeloperoxidase; GO/MPO), nitric oxide, peroxynitrite
and hydroxyl radicals (OH*) generated from peroxide/Fe3-EDTA, all in a cell-free system. Each value is the mean þ S.D. count collected over
100 s with a 1-s gate time, and is representative of six separate observations. *P6 0.01 vs background (23 þ 2 cps) and **P6 0.01 vs non-en-
hanced.
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eases, such as asthma [3]. The ability of eosinophils to secrete
lipid mediators, basic proteins and reactive oxygen and nitro-
gen species appears to contribute to the actions of these cells
[4^9]. Here we demonstrate that eosinophils produce 1O2 in
response to endogenous in£ammatory mediators.
MVP has been cited as a speci¢c enhancer of chemilumi-
nescence from 1O2. We have con¢rmed this by showing that
chemiluminescence produced in the presence of glucose/glu-
cose oxidase/myeloperoxidase was not SOD-inhibitable, and
that no chemiluminescence was evident with xanthine oxidase/
acetaldehyde. Isolated guinea pig eosinophils activated with
nM concentrations of the physiological agonists C5a and
LTB4, or with the PKC activator PMA, produced 1O2.
SOD did not block the production of 1O2, whilst it completely
quenched superoxide detected by lucigenin chemilumines-
cence. Inhibition of nitric oxide synthase by pre-incubation
with L-NIO, preventing formation of ONOO3 which can elicit
MVP chemiluminescence, did not a¡ect the emission resulting
from activation. In addition, when activated with C5a or
LTB4, eosinophil singlet oxygen production was comparable
with that elicited using WM levels of PMA. However, 1O2
production by the former was faster to reach a maximum,
but more transient compared with PMA, which was slower
in onset and sustained for a longer period. This is consistent
with our previous studies evaluating the e¡ects of similar
stimuli on eosinophil aggregation and production of ROI
[12,17]. Thus, under these conditions, eosinophil activation
by physiological stimulators such as LTB4 and C5a was rapid
in onset and transient, whereas the e¡ect of PMA was slower,
but more sustained.
Further evidence that in£ammatory cells can produce 1O2
has been provided by Steinbeck et al. [18] who used 9,10-
diphenylanthracene-coated beads as a 1O2 trap, and demon-
strated 1O2 generation by phagocytic neutrophils, which ac-
counted for 20% of the oxygen consumption. It is recognised
that 1O2 is an important cytotoxic species in cell killing medi-
ated by monocytes, neutrophils and eosinophils (reviewed in
[19]). The ability of 1O2 to avidly attack cellular targets pro-
tected from other less damaging species supports this [20]. The
fact that physiological modulators of in£ammatory cells can
induce production of 1O2 is signi¢cant not only to parasite
killing, but also in damage to host targets such as lung epi-
thelial cells in asthmatic patients. We are at present addressing
this in animal models of allergic airway disease and parasite
killing in vitro.
The mechanism by which eosinophils produce 1O2 is pro-
posed to involve H2O2 and hydrohalogenated acids [21], how-
ever 1O2 can also be produced from the interaction of H2O2
with either peroxynitrite or NO [22,23]. Eosinophils produce
both NO and superoxide, however the addition of SOD to
activated cells did not change the 1O2 production, implying
that peroxynitrite was not a source of 1O2.
In summary, we have demonstrated for the ¢rst time that
eosinophils when activated by physiological e¡ectors release
1O2, and that this occurs in the absence of added bromide.
Fig. 2. Singlet oxygen and superoxide production by PMA-activated
eosinophils. a: Time-dependent MVP-enhanced chemiluminescence
following activation with 0.1 and 1.0 WM PMA. Each value is the
mean þ S.D. chemiluminescence count collected over 100 s with a
1-s gate time, and is representative of four separate observations.
b: E¡ect of SOD and a 460^500-nm ¢lter on MVP- and lucigenin-
enhanced chemiluminescence in PMA (1.0 WM)-activated eosino-
phils. Each value is the mean þ S.D. count 10 min after PMA addi-
tion, collected over 100 s with a 1-s gate time, and is representative
of four separate observations.
Fig. 3. E¡ect of peroxynitrite, singlet oxygen and hydroxyl scav-
engers on MVP chemiluminescence in PMA-activated eosinophils.
Cells were preincubated either with L-NIO or with histidine and
mannitol added 10 min after PMA activation, the period of maxi-
mum chemiluminescence. Each value is the mean þ S.D. count 10
min after PMA addition, collected over 100 s with a 1-s gate time,
and is representative of four separate observations.
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Fig. 4. Singlet oxygen production by C5a- or LTB4-activated eosi-
nophils. Each value is the mean þ S.D. MVP chemiluminescence
count for each time point, collected over 100 s with a 1-s gate time,
and is representative of four separate observations.
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